Autism as a disorder of neural information processing: directions for research and targets for therapy by Belmonte, MK et al.
Autism as a Disorder of Neural Information Processing:
Directions for Research and Targets for Therapy 1
Copyright c©2004 by the authors listed below. All rights reserved.
AN ABRIDGED VERSION OF THIS PAPER APPEARS IN
MOLECULAR PSYCHIATRY, 2004, doi:10.1038/sj.mp.4001499
Matthew K. Belmonte Edwin H. Cook, Jr.
Autism Research Centre Departments of Psychiatry,
Departments of Psychiatry and Pediatrics, and Human Genetics
Experimental Psychology University of Chicago
University of Cambridge, UK Chicago, Illinois, USA
George M. Anderson John L.R. Rubenstein
Child Study Center Department of Psychiatry
Yale University University of California San Francisco
New Haven, Connecticut, USA San Francisco, California, USA
William T. Greenough Andrea Beckel-Mitchener
Beckman Institute Beckman Institute
University of Illinois University of Illinois
Urbana-Champaign, Illinois, USA Urbana-Champaign, Illinois, USA
Eric Courchesne Lisa M. Boulanger
Department of Neurosciences Department of Neurobiology
University of California San Diego Harvard Medical School
La Jolla, California, USA Boston, Massachusetts, USA
Susan B. Powell Pat R. Levitt
Department of Psychiatry Kennedy Center for Research on
University of California San Diego Human Development
San Diego, California, USA Vanderbilt University
Nashville, Tennessee, USA
Elaine K. Perry Yong-hui Jiang
Centre Development in Clinical Brain Ageing Department of Molecular and Human Genetics
University of Newcastle Baylor College of Medicine
Newcastle, UK Houston, Texas, USA
Timothy M. DeLorey Elaine Tierney
Molecular Research Institute Kennedy Krieger Institute
Mountain View, California, USA Baltimore, Maryland, USA
1This paper is the report of the meeting ‘Pinpointing Autism: Neurochemical Targets and Research
Directions in Developmental Neurobiology’ convened by Cure Autism Now in Santa Monica, California,
April 2002. In addition to those workshop participants who have directly contributed to this review, we wish
to acknowledge the participation of of Michael Merzenich, Eric Hollander, Steven Watkins, Maja Bucan, and
Mark Geyer, whose insights have helped shape this discussion.
1
Abstract
The broad variation in phenotypes and severities within autism spectrum disorders
suggests the involvement of multiple predisposing factors, interacting in complex ways
with normal developmental courses and gradients. Identiﬁcation of these factors,
and the common developmental path into which they feed, is hampered by the large
degrees of convergence from causal factors to altered brain development, and divergence
from abnormal brain development into altered cognition and behaviour. Genetic,
neurochemical, neuroimaging and behavioural ﬁndings on autism, as well as studies
of normal development and of genetic syndromes that share symptoms with autism,
oﬀer hypotheses as to the nature of causal factors and their possible eﬀects on the
structure and dynamics of neural systems. Such alterations in neural properties may
in turn perturb activity-dependent development, giving rise to a complex behavioural
syndrome many steps removed from the root causes. Animal models based on genetic,
neurochemical, neurophysiological, and behavioural manipulations oﬀer the possibility
of exploring these developmental processes in detail, as do human studies addressing
endophenotypes beyond the diagnosis itself.
The past several years of research on autism and brain development have produced a
conﬂuence of ﬁndings that point the way towards understanding this complex behavioural
syndrome in terms of its developmental roots. Imaging and behavioural studies on one
front and genetic and biochemical studies on the other are converging on a view of autism
as the result of pervasive, early developmental abnormalities aﬀecting neural information
processing. Such dysfunctions may arise through the interactions of many determinants,
each of which contributes diﬀerently to the ﬁnal phenotypic proﬁle. Examination of speciﬁc
phenotypic components within the broad syndrome of autism promises to identify these
underlying factors.
1 Autism and Abnormal Neural Dynamics
Key to the understanding of autism is its recognition as a developmental disorder – developmental
not simply in terms of taxonomy but in terms of its detailed aetiology. The approach in most
studies has been to attempt to dissect autism as if it were a lesion, a missing locus or capacity
within an otherwise normal, fully developed brain in which all other factors have somehow
been held constant. This approach is inappropriate to the study of developmental disorders
because it assumes that the disorder is a function of a localised module, rather than an
emergent property of developmental interactions between many brain regions and functions
[129]. Cognitively, autism has been construed as a disorder involving fundamental deﬁcits
in central coherence [91], executive function [166], and theory of mind [21] or empathising
[18] – these descriptions are neither mutually exclusive nor mutually independent, and a
complete explanation will encompass all of them. Anatomically, abnormalities associated
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with autism have been localised in cerebellum [74, 161, 73, 105], brain stem [105, 194], frontal
lobes [42, 67, 215, 11], parietal lobes [69], hippocampus [12, 203] and amygdala [12]. While
signiﬁcant abnormalities are present in all these cognitive capacities and anatomical regions,
it remains to be seen how these characteristics are related to each other and to autism’s
fundamental causes. Past research has focused on the leaves of the developmental tree –
the collection of surface features that are diagnostic or most apparent in autism. In order
to understand autism as a developmental syndrome it is necessary to explore development
at its trunk and roots. It is in this way that the two fronts of autism will be joined,
unifying abnormal structure and function with the underlying genetics and neurobiology,
and providing speciﬁc targets for therapeutic intervention.
Looking beyond surface features is a challenge for autism research: primary dysfunctions
can be masked by the evolution of compensatory processing strategies which normalise
behaviour [200], and also by the induction of activity-dependent secondary dysfunctions
[66, 2] which disrupt behaviour in new ways. There is thus a high degree of fan-out
(divergence) from core dysfunctions in the developing brain to cognitive and behavioural
symptoms in the developed brain. The sheer number of genetic susceptibility factors and
loci that have been linked to autism implies that autism’s core dysfunction admits a high
degree of fan-in (convergence) from primary biasing factors to core dysfunctions. The
60% concordance for strictly diagnosed autism in identical twins [88] establishes a role for
environmental interactions in this fan-in just as surely as it does for genetic predispositions.
The very breadth of autism’s anatomical and functional abnormalities admits the possibility
that its core dysfunctions may involve some pervasive alteration of neural processing. One
route to such an alteration might be via abnormally low signal-to-noise in developing neural
assemblies, a condition that may be produced by abnormal neural connectivity. The high
incidence of epilepsy in autism [16] is consistent with this hypothesis, and there has been
no shortage of relevant neuropathological ﬁndings. The numbers of Purkinje cells, and
to a lesser extent granule cells, in cerebellar cortex are abnormally low [262, 192, 24,
25] – presumably leading to disinhibition of the cerebellar deep nuclei and consequent
overexcitation of thalamus and cerebral cortex. Neurons in hippocampus, amygdala, and
other limbic regions are abnormally densely packed [24, 25, 187], and a Golgi analysis
of the hippocampus in two autistic brains [187] has revealed an abnormally low degree
of dendritic branching. A recent photographic examination of neurons in several cortical
regions suggests a reduction in the size of cortical minicolumns in the autistic brain, and an
increase in cell dispersion within minicolumns – characteristics that could increase the total
number of minicolumns and thus the degree of connectivity between minicolumns [44, 45].
It is important to note that a decrease in signal-to-noise can arise from abnormalities of
connectivity in either direction: whereas an overconnected network passes so much noise
that it swamps the signal, an underconnected network passes so little signal that it becomes
lost in the noise. In either case, large segments of the network are constrained to either an
all-on or an all-oﬀ state, and the network’s information capacity is thereby reduced [54].
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2 Neurophysiologic and Neuroanatomic Eﬀects
2.1 Neurophysiological Consequences
Such a failure to delimit activation within an abnormally connected network may be observable
as hyper-arousal in response to sensory input, and decreased ability to select among competing
sensory inputs [29]. Cardiovascular, neuroendocrine and neurochemical indices of arousal in
novel and stressful situations are consistent with this prediction [229, 124], as are physiological
and behavioural observations of the extent and intensity of perceptual processing. Physiologically,
functional imaging has demonstrated heightened activity in autism in brain regions associated
with stimulus-driven, sensory processing, and decreased activity in regions that normally
subserve higher-order processing: these results include abnormally high activity in ventral
occipital visual areas during a visual task demanding separation of local features from
global context (the Embedded Figures Test), even while prefrontal and parietal activations
are abnormally low [190]; heightened activity during face processing in peristriate cortex
[76], inferior temporal gyrus [205], and other areas outside the fusiform ‘face area’ [174]
while fusiform activity is abnormally low; heightened activity in superior temporal gyrus
during inference of mental state from pictures of eyes, while prefrontal and medial temporal
activations are abnormally low [22]; and decreased connectivity between extrastriate visual
areas and prefrontal and temporal areas associated with inference of mental state, while
prefrontal and temporal activations are again abnormally low [48].
Supporting the idea of impaired selection of perceptual inputs, evoked potential and
quantitative EEG studies reveal a pattern of abnormally distributed response in autism
during tasks that demand selective attention. In adults with autism, the P1 evoked potential
is either abnormally augmented in response to stimuli at the attended location, or abnormally
generalised to stimuli distant from the attended location [233]. During shifts of attention
between hemiﬁelds, the normal, spatiotopically selective augmentation of the visual steady-
state evoked potential is absent, and instead both hemispheres activate indiscriminately
during shifts of attention into either hemiﬁeld [27, 29]. In children with autism, the visual
N2 to novel stimuli is augmented during task performance even when these stimuli are not
relevant to the task [133]. When a response is required to an auditory stimulus, the P3 in
these same children with autism is abnormally generalised to occipital sites overlying visual
processing areas [134]. In general, both in children and in adults, perceptual ﬁltering in
autism seems to occur in an all-or-none manner, with little speciﬁcity in selecting for the
location of the stimulus, for the behavioural relevance of the stimulus, or even for the sensory
modality in which the stimulus appears.
Recent fMRI evidence suggests that the autistic brain may compensate for this deﬁcit
in selecting sensory inputs by suppressing any irrelevant sensory information at a later, less
eﬃcient stage of processing [29]. In other words, in the absence of a normally functional
mechanism to bias sensory processing towards attended stimuli, all stimuli receive much the
same degree of sensory evaluation, and the irrelevant stimuli must then be actively discarded
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in a manner that creates a processing bottleneck. Perhaps because such a compensatory
mechanism cannot be as quickly reset as the normal mechanism of selective attention,
performance is impaired at tasks that demand rapid reconﬁguration of perceptual resources
[36]. An autistic deﬁcit in rapid shifting of attention has been observed in cases of shifts
between sensory modalities [71], between spatial locations [246, 247, 234, 236, 235, 104,
27], and between object features [72, 189]. Even when the demand for rapid shifting
is eliminated and people with autism produce normal behavioural output, physiological
measures remain abnormal, indicating the operation of compensatory processing: frontal
negativities associated with sustained attention are reduced or absent in the autistic brain
[68, 53], the frontal late positive component to peripheral visual stimuli is delayed [237], and
the visual P3b is highly variable [68] with a somewhat low average amplitude [162, 53, 244,
237].
2.2 Developmental Connections
These abnormalities of perceptual processing point to a developmental explanation for higher-
order abnormalities, an explanation that depends crucially on the idea of a developmental
chain of abnormal function: when a developing brain is confronted with an abnormal
constraint on information processing, it will evolve an abnormal organisation in order to
accommodate that constraint [129]. It is via such a chain of dysfunction that a core deﬁcit
such as degraded neural signal-to-noise could fan out into a welter of autistic behavioural
abnormalities. From the earliest months of infancy, the ﬂood of input generated by over-
aroused, under-selective primary processing would overload nascent higher-order cognitive
processes [29] – systems whose development may be being independently sabotaged by the
same neuropathology that aﬀects primary regions. Such an eﬀect may explain the extension
of sensory and motor activations in adults with autism into territories that normally subserve
later-maturing cognitive functions [160]. Depending on its timing, such an error of neurocognitive
development might underlie loss of cognitive skills or failure to develop skills.
Faced with this bottleneck in higher-order cognition, the developing and plastic brain
would likely evolve a cognitive style that avoids reliance on high-level integrative processing
and instead emphasises low-level features – a pattern typical of autistic attention and
perception which Frith has termed weak central coherence [91]. Central coherence, in Frith’s
deﬁnition, is the drive that causes fragmentary features to lose their identity as separate
fragments once they are assembled into a single object; it is the eﬀect of context on meaning.
Weak central coherence is of especial interest as part of an explanatory framework since
since it predicts not only autism’s cognitive impairments in integrative tasks but also its
cognitive advantages in tasks that demand attention to detail. People with autism perform
better than normal on the Embedded Figures Test [206], a task that demands recognition
of individual features within spatial arrangements. Unlike normal subjects, they are not
aided by pre-segmentation of patterns in the Wechsler Block Design subtest, and when
they make errors, these are more likely to be ones of global conﬁguration rather than local
detail [207]. In many high-functioning children with autism, lexical-to-phonological decoding
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based on words’ small-scale features outpaces comprehension, producing a condition known
as hyperlexia [261]. Perhaps because they process faces as collections of individual features
rather than as centrally coherent gestalts, children with autism are impaired at recognising
unfamiliar faces [33, 136] and show a reduced or absent face-inversion eﬀect [111, 224].
Again presumably because of intense processing of individual features, the normal levels-of-
processing eﬀect on memory is inverted in autism, with rote memory superior to normal,
and memory for semantic associations impaired [228]. This piecemeal approach to perception
is mirrored by a failure to generalise special skills to broader domains – e.g. the calendar
calculator who has no interest in other forms of arithmetic calculation.
Autism’s weakened central coherence may thus be a secondary property, emerging in the
interaction of normal cognitive development with abnormal neural information processing
– an interaction that encourages an unusual cognitive dependence on low-level processing
of individual details. Indeed, the presence of low-level perceptual abnormalities in autism
[181] has contributed to a recognition that many higher-level cognitive abnormalities may
best be characterised as the eﬀects of a surfeit of local processing rather than any speciﬁc
impairment in global processing [180], and to an appreciation of the role of compensatory
developmental changes surrounding altered perceptual functioning [159]. The possibility
that some of autism’s cognitive symptoms may develop as compensatory or accommodative
changes raises the possibility of targeted behavioural and pharmacological interventions –
one could, for example, imagine an early intervention aimed at preventing the developing
brain from relying so exclusively on its intact processing of local features, in somewhat the
same manner as an eye patch prevents a child at risk for amblyopia from relying on the
intact eye.
Weak central coherence may in turn form the cognitive underpinning of a wide array of
developmental behavioural disturbances, by impairing the use of contextual information in
complex perceptual and executive tasks [93]. The executive deﬁcit deﬁned by this inability
to use context may impact performance on theory-of-mind tasks [201], which depends on
an ability to apply the context contained in one’s inner model of another person’s mental
state. Such an exective deﬁcit may also impede the development of joint attention and
shared aﬀect [137, 195], processes in which response to stimuli depends crucially on social
context. The resulting poverty of early social cognitive experience may perturb or prevent
the further activity-dependent development [66, 2] of specialised modules or capacities for
such tasks as face processing, language, and complex social relations involving theory-of-mind
and empathising. This failure to use context and to apply a theory of mind may result in a
style of unsupervised learning founded on statistical associations rather than learning that
is directed by the intentionality of others [92], and to a preference for ritualised, scripted,
and repeatable interactions. Autism’s surface symptoms might thus be understood as the
developmental reaction of a normal human mind to abnormal neural hardware.
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2.3 Anatomical Correlates
Partly because of the diﬃculty in recruiting people with autism who can tolerate task
demands within the scanner environment, functional MRI has begun to be applied to
autism only recently. Structural MRI, on the other hand, is an established technique.
In adolescents and adults with autism, MRI morphometry has revealed volume deﬁcits in
cerebellum [74, 161, 73, 105], brain stem [105], and posterior corpus callosum [84]. As is
the case with behavioural measures of autism, anatomical measures reveal subgroups: a
minority of patients show increased rather than decreased cerebellar volume [70], and nearly
half have a volume deﬁcit in the parietal lobe [69] which is associated with a narrowing of
the spatial focus of attention [233]. This anatomical heterogeneity likely reﬂects diﬀerent
convergent routes to, divergent routes from, or correlates of a common dysfunction. Studies
of adult subjects say comparatively little about what this common dysfunction may be, since
observations in adults take place long after the developmental pathology has run its course:
although the underlying dysfunction may still exist in these adults, it can be expected to have
been hidden by a forest of secondary dysfunctions and adaptive or compensatory changes.
Longitudinal studies using MRI volumetric and head circumference data point to the
conclusion that autism involves transient postnatal macrencephaly [64]. Although non-
standardised measurements of head circumference must be viewed with some caution, the
data currently available on newborns later diagnosed with autism or PDD-NOS suggest that
head size at the time of birth is normal or perhaps even slightly smaller than normal [65].
By 2 to 4 years of age, 90% of these children have MRI-based brain volumes larger than the
normal average [42, 67, 215, 11], and group measures of head circumference have increased
correspondingly. This abnormal brain growth is due primarily to excessive enlargement
of cerebellar and cerebral white matter and cerebral grey matter [67, 108]. Even in older
children, enlargement of superﬁcial white matter tracts containing cortico-cortical ﬁbres
may persist, while internal capsule and corpus callosum are proportionately reduced [109].
Deviation from normal is so common and extreme that cerebellar and cerebral white matter
volumes together with cerebellar vermis size accurately distinguish 95% of autistic toddlers
and young children from normal children, and also accurately predict whether a young
child with autism will have a low or high functioning developmental outcome [67]. These
two-to-four-year-old autism patients show an anterior-to-posterior gradient of overgrowth,
with frontal lobes being the largest [43]. This early abnormality creates a lasting legacy of
increased head circumference throughout life, but, in most cases, not a lasting macrencephaly.
By adulthood, then, macrencephaly is not typically present in autism, and brain volumes
tend to be near normal. In sum, an abnormally rapid increase in brain volume in early life
in autism is followed by abnormally slowed or prematurely arrested growth in cerebellar and
cerebral regions. This early brain overgrowth takes place during a period which in normal
development involves changes in synaptic density [117]. The increase in the volume of cortical
grey matter matter may reﬂect a failure of synaptic pruning or a surfeit of synaptogenesis,
and may thus be the earliest gross anatomical manifestation of a pervasive abnormality in
the development of neural assemblies. Of equal potential importance, the increased volume
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of local white matter projections suggests abnormality in the normal postnatal process of
rapid myelination.
In characterising this underlying abnormality, it is important to note that a general
deﬁcit in development may interact with normal developmental gradients to produce an
anatomically and functionally speciﬁc pattern of deﬁcits. Myelination, for example, is not
uniformly controlled across the cerebral hemispheres, but instead develops in a posterior to
anterior direction. The persistence of myelination into the third decade of life in frontotemporal
but not occipitoparietal ﬁbre tracts [264, 28] indicates that oligodendrocyte regulation diﬀers
regionally. Likewise, changes in the development of neuronal populations can arise in a
regionally selective fashion: in a targeted mutation of the hepatocyte growth factor signalling
system, for example, deﬁcits of GABAergic neurons appear only in frontal and parietal
cortices, and only in the parvalbumin-containing subpopulation of cells [184]. In terms of
cellular and molecular relationships just as in the case of cognitive ones, it may be fruitful to
view autism as a product of the interaction of normal development with abnormal contraints.
Observations of abnormal patterns of early brain growth suggest that at least a portion of
this interaction occurs postnatally. This postnatal time frame for pathogenesis oﬀers hope
of early biological interventions, if the genetic and neurochemical determinants of abnormal
growth can be identiﬁed.
3 Neurobiological Bases
3.1 Genes
It has become increasingly clear that genetic factors are very signiﬁcant determinants of
autism pathophysiology. The risk that another sibling will be born with autism to parents
who have already had an autistic child is approximately 4.5% [130]. Given recent estimates of
population prevalence for autism (which have increased, partly as a result of more complete
ascertainment) [50], this statistic represents a sibling recurrence risk over twenty times
the risk for the general population. Moving from siblings in general to identical twins in
particular, the increased risk of concordance for autism rises from twentyfold to over two
hundredfold. Such a large diﬀerential suggests not only the involvement of multiple genes,
but also a multiplicative eﬀect among these genes. For example, if there were ﬁve genes
involved, a twentyfold increase could be accumulated from risk multipliers as small as 1.8
for each gene. Although some estimates of the number of interacting genetic loci in autism
are as low as two to ten [172], others range from over ﬁfteen to over a hundred [191, 186].
This multiplicative mode of inheritance carries implications for the nature of the genetic
factors involved, for the experimental discriminability of each individual factor, and for the
potential of interventions targeting these factors. Multiplicative eﬀects arise from interactions
between individual genes, and the susceptibility factors for autism are therefore likely to
inﬂuence gene expression or to encode subtle functional alterations in proteins that participate
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in regulatory networks. Multiplicative inheritance also means that the small eﬀect of each
gene by itself will be diﬃcult to identify and to conﬁrm; each genetic variant is likely to
act as “the straw that breaks the camel’s back,” innocuous by itself but pathological in
concert. Although these small eﬀect sizes will be diﬃcult to discern, the advantage in
terms of treatment is that intervening to restore regulation to a single gene or to a small
set of genes may diminish the multiplicative eﬀect enough to yield large preventative or
therapeutic eﬀects. This situation in which the disorder may be approached via any of
several therapeutic targets stands in contrast to monogenic disorders where there may not
be an obvious therapeutic strategy before decades of basic work (e.g. Huntington’s disease).
A further consequence of the multiplicative model is that the prevalence of individual
risk alleles in the general population will be high. Most if not all of these autism ‘risk’ alleles
are likely to have some adaptive value, in cases where they do not lead to autism. In some
cases this adaptive value would be obvious (e.g. enhancement of focused attention or other
elements of neuropsychological function). In other cases the beneﬁts to humanity of the
existence of these alleles may be more diﬃcult to determine, but are likely to be present.
Although review of the current status of identifying genetic risk factors for autism is
beyond the scope of this manuscript, several thorough reviews are available [59, 88, 143, 141,
60]. Two relatively small regions, on 15q11-q13 centred around the GABAAβ3 receptor
subunit gene (GABRB3) and near the serotonin transporter (SLC6A4) on 17q11.2, are
locations where more than two, but not all, studies have shown family-based association with
autism. In addition to 17q, several other regions of the genome including 2q and 7q appear to
be involved in the larger syndrome based on convergence from several studies. Fine mapping
of these regions should be a priority in addition to generating larger samples in which two or
more siblings have autism in a family (e.g. the Autism Genetic Resource Exchange (AGRE)
[95]). In Turner syndrome, an interesting ﬁnding of increased risk for autism after deletion
of the paternal, but not maternal X chromosome, suggests that a protein expressed only
when the paternal X chromosome is present may be protective from autism. Such a protein
might be expressed only in the developing female brain, perhaps accounting in part for the
approximate 4:1 ratio of males with autism to females with autism [212]. Another possible
explanation is that some of autism’s several ‘risk’ alleles are on the X chromosome.
At least four X chromosome loci have already been implicated in autism, including
neuroligin 3 (NLGN3), neuroligin 4 (NLGN4), FMR1 (see below), and MECP2. Although
rare, a possibly functional missense mutation has been identiﬁed in NLGN3 in an aﬀected
sibling pair, and a de novo nonsense mutation of NLGN4 has been found in aﬀected siblings
and their unaﬀected mother [126]. Discrepancies between the aﬀected status of the mother
and oﬀspring are somewhat diﬃcult to interpret since, as the authors note, strong sequence
conservation exists between NLGN4 andNLGN4Y. Nevertheless, the association of neuroligins
with autism is of great interest in light of the idea that autism’s pathophysiology may begin
with abnormal neural connectivity.
The ﬁrst truncating mutations in an autism-related disorder were reported when mutations
in MECP2 were identiﬁed in Rett syndrome [5]. The function of MECP2 is to turn oﬀ
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several genes whose promoters have been methylated. Therefore, in addition to FMR1 and
UBE3A discussed below, mutations in MECP2 contribute to neurobiological dysfunction due
to dysregulation of networks of temporally and spatially regulated genes. The recent ﬁnding
of 2 de novo mutations of MECP2 in a screen of 69 females with autism [41] shows that
MeCP2, and perhaps its regulatory targets, are likely to be a contributing factor in autistic
pathology.
In summary of the current ﬁndings, there is as yet no conﬁrmed genetic ﬁnding in autism
that has been explained in terms of its speciﬁc relation to brain development. In order
to understand what genetic factors may inﬂuence the developmental processes that lead to
autism, it is useful to focus on syndromes whose symptoms overlap with those of autism
and which may be more tractable in terms of our current knowledge of biological cause and
eﬀect.
3.2 Proteins that Regulate Gene Expression
One such symptomatically overlapping disorder is Fragile X syndrome (FXS). FXS is the
most common inherited form of mental retardation and second only to Down syndrome
overall. Its neurobehavioural phenotype is characterised by some combination of mild to
severe cognitive impairment, attention deﬁcit, anxiety, seizure susceptibility, communicative
disorders, and stereotypic behaviours. In addition, recent reports have suggested that 25-
40% of individuals with FXS also meet diagnostic criteria for autism [15, 196, 14]. Studies
of children with autism have shown a concurrence of FXS with autism of approximately 2%,
with one study ﬁnding the Fragile X mutation to be the most frequent chromosomal anomaly
associated with diagnosed autistic cases [13, 256]. In many instances the behavioural proﬁles
observed in FXS seem indistinguishable from those of idiopathic autism – although some
studies have noted distinct diﬀerences especially in the realm of social and communicative
skills [55].
FXS is caused by the silencing of a single gene (FMR1) [175] that codes for the Fragile
X Mental Retardation Protein (FMRP), an RNA binding protein [9]. FMRP binds to
numerous mRNA cargoes, including its own mRNA, and has been hypothesised to regulate
the expression of a speciﬁc set of genes in neurons. When FMRP is absent, the expression
of these genes is altered and the FXS phenotype is observed. A critical feature of FXS,
therefore, is that what is in one sense a single-gene disorder is more proximally the result
of a disruption of complex patterns of expression of many genes. Using a novel technique,
Miyashiro et al. have recently demonstrated that multiple classes of mRNA molecules are
bound to FMRP in neurons [158]. In light of the high incidence of autistic behaviours in
FXS, the data set of approximately 80 genes whose mRNA’s bind to FMRP was screened
to reveal 15 that map closely to suspected autism susceptibility loci. It is interesting and
reasonable to speculate that polymorphic variations in these genes, and perhaps others to
be determined, may be related to the variable autistic phenotype observed in many patients
with FXS.
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An examination of FMRP’s expression and association with polyribosomal machinery
in the brain leads to three important concepts. First, some of the protein synthesis that
involves FMRP occurs at synapses in response to Group I metabotropic receptor activation
[257]. (Since not all FMRP-expressing cells receive synaptic input, though, it is likely that
not all protein synthesis involving FMRP is synaptic.) Second, FMRP itself is synthesised
in response to activation of metabotropic glutamate receptor subtypes 1 and/or 5. Third,
this process requires FMRP, since synaptic activity dependent protein synthesis is greatly
reduced in the FraX knockout mouse [99]. An interesting in vivo correlate of this observation
is that the proportion of dendritic spines that contain polyribosomal aggregates is reduced
in the cortices of knockout mice. Therefore, one physiologically based hypothesis is that
FMRP regulates the local expression of a subset of genes by controlling their translation in
response to neuronal activity.
Behavioural exposure to a complex environment increases FMRP expression in rat visual
cortex [121], as do physical activity in the case of somatomotor cortex [121] and whisker
stimulation in the case of barrel cortex [227]. Knockout of the FMR1 gene in mice increases
dendritic spine density in visual cortex [56]. Similarly, in barrel cortex, a natural process of
developmental dendritic regression fails to occur in the knockout mouse [94]. Taken together,
these ﬁndings provide strong evidence for a critical role of FMRP in protein syntheses
involved in activity-dependent brain development, and speciﬁcally in the patterning of neural
circuitry. Anatomically, in FXS there is an overabundance of long, thin dendritic spines and
a relative reduction in the number of short, thicker spines in cortical regions examined
(e.g. [110, 56, 122]). Although the FXS patients from which these microanatomical results
arise were not speciﬁcally diagnosed with autism, the symptomatic and possible aetiological
overlap between FXS and autism makes these observations relevant to the understanding of
autistic neuropathology. The alteration in spine morphology suggests an abnormally large
proportion of immature synapses. The fact that there are more long, thin spines, and more
spines overall, may reﬂect a failure of the synapse elimination that would normally occur
during early development. A study of the hippocampal formation in idiopathic autism [187]
described reduced dendritic ﬁeld size in pyramidal neurons in the Ammon’s horn region, a
result that contrasts with the FXS ﬁndings (in other brain regions) and suggests either a
failure to fully reach adult form (the authors’ interpretation) or an increase in the amount
of pruning in the autistic cases, the opposite of what is reported in barrel cortex [94]. Either
sort of change, an abnormal abundance of dendritic connections or an abnormal lack of
them, could lead to diﬃculty in information processing due to reduced signal-to-noise. The
diﬃculty in diﬀerentiating these two scenarios suggests that other methods are needed to
converge on the capacity of structurally-altered brain regions for information processing.
The question remains as to why 25-40% of FXS cases have symptomatic similarity
to autism and why other disorders such as Rett syndrome, Prader-Willi syndrome, and
Angelman syndrome may have similar symptoms as well. This neurobehavioural similarity
suggests something common to the aetiology or something common to the outcome in each
disorder. One example of an aetiological commonality is that of interacting genetic factors,
such as the FMRP cargo genes that map to loci associated with autism. The broad range
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of severities and features in the FXS phenotype may reﬂect interaction with polymorphisms
in such genes.
Common outcomes are perhaps more challenging to understand, but the possibility exists
of relatively stable or “trapping” end points that may be reached via fan-in from multiple
pathways and, once entered, are very diﬃcult to overcome. For example, one might imagine
that the autistic symptoms exhibited in FXS and in idiopathic autism serve a purpose with
respect to their neurobehavioural contexts by reducing, say, high levels of anxiety. Thus any
attempt to overcome these symptoms serves to increase anxiety and hence elicits opposition
and persistence of symptoms. It is also possible that symptoms such as chronically repeated
stereotypic movements oﬀset some tension at the neural level rather than the cognitive or
behavioural level. In either case, behaviour would become reinforced into a pathological
state. Neural network modellers have used the term “stable attractor” to delineate states
of their networks with similar properties. Whether this conceptualisation is useful remains
to be determined, but it seems clear that understanding what underlies the similarities and
diﬀerences between FXS and autism may oﬀer signiﬁcant insight into the complexity of both
disorders.
FMRP, of course, is not the only regulatory protein with a possible association with
autism. The abnormalities in 15q11-q13 are of especial interest because of the association of
a known gene in 15q11-q13 with two neurogenetic disorders, Prader-Willi syndrome (PWS)
and Angelman syndrome (AS), and overlapping clinical features between AS and autism.
The AS gene, UBE3A, is maternally expressed only in brain tissue and codes for a ubiquitin
protein ligase, an enzyme that can regulate the levels of many intracellular proteins by
labelling them for ubiquitin-mediated degradation. UBE3A abnormalities thus are capable
of producing a wide range of fan-out eﬀects.
The majority of patients with PWS or AS have a deletion of 15q11-q13, on the paternal
chromosome in PWS and on the maternal chromosome in AS [127]. In contrast, a smaller
fraction of PWS and AS patients have uniparental disomy for chromosome 15, with two
paternal chromosomes causing AS and two maternal chromosomes causing PWS. In each
case the balance between maternally and paternally derived genes is altered; however, in the
case of deletion the aetiology is clearly genetic, whereas in the case of uniparental disomy it is
epigenetic: in these disomic individuals there is no abnormality of the genomic sequence, yet
the phenotype is indistinguishable from that caused by genetic deletion. Epigenetic disease
of this sort may be more common than previously considered [26]. Similar phenomena may
be operating in autism, with both genetic and epigenetic alterations contributing to autism
susceptibility.
Despite the association of autism with maternal duplication of 15q11-q13, interstitial
duplications in the homologous region on the paternal chromosome are associated with
a relatively normal phenotype. These data strongly suggest that there is an imprinted,
maternally expressed gene or genes within 15q11-q13, epigenetically-induced over-expression
of which can contribute to autism. The best studied form of epigenetic modiﬁcation is DNA
methylation, and abnormalities of DNA methylation and/or its eﬀects are implicated in
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several genetic diseases whose clinical features overlap with those of autism, including FXS,
PWS, AS, and Rett syndrome. The dynamic changes in DNA methylation that occur during
early embryonic development and during germ cell development provide ample opportunity
for germ-line or somatic errors in epigenetic processes, ‘epimutations’ [188]. If an abnormality
of DNA methylation were proven in autism, an immediate therapeutic intervention could
be explored using drugs or dietary manipulations known to alter DNA methylation, such as
folate supplementation.
Success in modelling Angelman syndrome in UBE3A knockout mice suggests that murine
15q11-q13 manipulations may also hold promise for the development of an animal model of
autism. Mice with maternal deﬁciency of UBE3A recapitulate the human AS phenotype
with motor dysfunction, seizures, deﬁciency in contextual learning, and impairment in
hippocampal long-term potentiation [128]. The role of 15q11-q13 in autism can be dissected
by making mice with various locus-speciﬁc duplications [267] of the homologous PWS/AS
domain. This approach may produce a valid mouse model for autism even before a speciﬁc
autism-related gene within 15q11-q13 is conclusively identiﬁed.
3.3 γ-Aminobutyric Acid
The 15q11-q13 region also codes for several subunits of the GABAA receptor, an ionotropic
receptor whose hyperpolarising eﬀect is mediated by chloride. GABRB3, GABRA5 and
GABRG3 (encoding the GABAA receptor’s β3, α5, and γ3 subunits, respectively) all are
clustered within 15q11-q13, and there is evidence for association with autism of genes in
this chromosomal region [38]. The increased incidence of epilepsy in patients with autism
and 15q11-q13 duplications is consistent with the involvement of GABA. Hippocampal
GABAA receptor binding in autism is abnormally low [31], as are platelet GABA levels [198].
GABAergic interneurons have a special role in establishing the computational architecture of
cortical columns; double bouquet interneurons, for example, send axon bundles from layers
2 and 3 to synapse on pyramidal and spiny stellate cells in columnar arrangements [80, 170].
In addition, GABAergic neurons may be particularly vulnerable to developmental errors,
since they arise from a diﬀerent portion of the neural tube than the excitatory cells with
which they integrate: GABAergic cells migrate into neocortex from the primordium of the
basal ganglia [8].
GABAergic transmission in the mature brain plays primarily an inhibitory function. In
the forebrain GABAergic neurons have a number of central roles. For instance, GABAergic
projection neurons of the basal ganglia are an essential link in the extrapyramidal circuit.
GABAergic projection neurons of the reticular nucleus regulate thalamic function. GABAergic
local circuit neurons have essential roles in information processing in the cerebral cortex,
hippocampus and olfactory bulb. Thus, reduced function of GABAergic neurons would
aﬀect most aspects of forebrain function. Primary sensory information would reach the
cerebral cortex, but the intrinsic and basal ganglia circuits that process this information
would be abnormal. Furthermore, several regions of the forebrain would be hyper-excitable.
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These characteristics resemble our present understanding of features of the autistic mind,
and reﬂect the fact that many people with autism have epilepsy and high levels of anxiety.
Recent genetic studies in mice suggest molecular mechanisms that could underlie this
pathological physiology [199]. Mice lacking the GAD65 gene, encoding an enzyme that makes
GABA, have defective cortical plasticity that can be corrected with a GABA agonist [107].
Mutations in the Dlx1 and Dlx2 genes disrupt development of most telencephalic GABAergic
neurons [8, 153]. It is worth noting that the human locus that has the highest LOD score for
autism susceptibility (D2S2188 on chromosome 2q) maps very close to both the GAD65 and
the Dlx1 and Dlx2 genes [118]. Furthermore, the autism susceptibility locus (D7S477) on
chromosome 7q maps within about six megabases of the Dlx5 and Dlx6 genes. These genes
are also implicated in regulating forebrain GABAergic development [218, 219, 148] [Cobos
and Rubenstein, unpublished]. Also in this region is the gene for reelin, a protein expressed
in cortical GABAergic neurons [3].
One of the GABAA receptor subunit genes in particular, GABRB3, is highly expressed
during brain development in rats [142], and its deletion in mice disrupts GABA-related
pharmacology and electrophysiology and produces behaviours reminiscent of autism [82].
In mice homozygous for a disruption of GABRB3, GABAA receptor binding in neonatal
and adult brain is reduced by half, with most of this reduction occurring in cerebral cortex
and thalamus [125]. GABA function is impaired in these knockout mice in dorsal root
ganglia, hippocampus, and the thalamic reticular nucleus, with an 80% reduction in GABA-
activated chloride current in homozygotes and a 25% reduction in heterozygotes [125]. As a
result, GABRB3 knockout mice have epileptiform EEG containing high-amplitude slow and
sharp waves, and develop overt seizures as they mature [125, 82]. Behaviourally, GABRB3
knockouts are hypersensitive to thermal and tactile stimuli [239]. They are hyperactive,
exhibiting stereotyped circling [125, 82]. They lack motor coordination, often falling and
failing to learn a rotating-rod task [82]. Their cycles of rest and activity are lengthened
[82], and EEG spectral characteristics during slow-wave sleep are abnormal [263]. There
are also cognitive deﬁcits, as measured by abnormalities of passive-avoidance conditioning
and contextual fear conditioning [82]. Mothers homozygous for the GABRB3 knockout
fail to engage in normal nurturing behaviour, even towards their wild-type pups [125].
These similarities to autism suggest either a direct involvement of GABRB3 in autism, or
some GABA pathology that shares physiological or developmental eﬀects with the GABRB3
knockout.
Collectively these observations suggest that reduced GABA signalling is a candidate
mechanism that may contribute to the causation of autism. Perhaps the co-inheritance of
a combination of hypomorphic alleles that all aﬀect GABAergic tone is a basis for some
forms of autism. Eﬀorts should therefore focus on studying known genes in known autism
susceptibility loci that aﬀect development and/or function of the GABAergic system. In
particular, the exons and known regulatory elements of the Dlx1,2,5,6 and GAD1 genes
should be sequenced in autism patients and their family members. This analysis will identify
SNPs and potential function-altering mutations. Furthermore, GABAergic agonists should
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be considered as potential therapeutic agents for autism.
3.4 Acetylcholine
GABAergic dysfunction can be produced not only by direct alterations in GABA systems but
also by changes in neuromodulation of GABAergic neurons. Several neuromodulators may
be involved in such changes, potentially with synergistic eﬀects. Abnormal developmental
changes in the population of septal neurons in autism suggest a cholinergic abnormality:
septal neurons are excessive in younger and reduced in older individuals with autism [25].
Acetylcholine aﬀects performance during sustained attention [157], possibly by shifting the
dynamics of cortical networks so that aﬀerent inﬂuence predominates over intracortical
inputs [135]. In mice, knockout of the α4 nicotinic subunit produces reduced antinociception
and increased anxiety [154, 171]; abnormal pain sensitivity and anxiety both are features
of the autistic syndrome. In addition, nicotinic receptors are essential for normal early
synaptic development [75, 231] and thus nicotinic dysfunction may produce abnormal neural
microarchitecture.
The α4β2 nicotinic acetylcholine receptor is decreased in autopsied brains of adults with
autism [169, 145]. This deﬁcit is most pronounced in the cerebral neocortex, where the
α4β2 receptor subtype has an important regulatory eﬀect on GABAergic neurons [4]. The
decrease is selective; the other principal nicotinic receptor subtype, α7, is not involved.
Although normal levels of choline acetyltransferase suggest that cholinergic input to the
cerebral cortex and the cerebellum is intact, the level of BDNF in the basal forebrain has been
observed to be three times higher than normal [145]. In addition to its role in GABAergic
development outlined above, BDNF is involved in enhancing cholinergic transmission [112]
and in promoting the survival of developing cholinergic neurons of the basal forebrain [248].
This BDNF abnormality at the major source of forebrain cholinergic projection may therefore
be signiﬁcant for cholinergic function.
As these neurochemical results come from adult brains, it remains to be seen whether
nicotinic abnormality is present at early stages of autistic development. Cholinergic dysfunction
may be an indirect contributor to autistic development via its inﬂuence on GABAergic
neurons, a correlate of prior GABAergic dysfunction, or a direct contributor via its inﬂuence
on synaptic development. In vivo studies at early ages, using PET and MR spectroscopy,
will give further information on the role of acetylcholine in autism. Pharmacologic therapies
targeting the cholinergic system may be of value; there has been one report of success using
the acetylcholinesterase inhibitor donezipil to treat autistic symptoms of irritability and
hyperactivity [103].
3.5 Serotonin
There has been a growing interest in the role of serotonin (5-hydoxytryptamine, 5-HT) in
autism since the initial report of elevated levels of platelet 5-HT in individuals with autism
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[204]. An increasing awareness of 5-HT’s critical involvement in guiding neurodevelopment
and in modulating sensory input and arousal has provided a convincing theoretical basis
for 5-HT’s role in the aetiology and pathophysiology of pervasive developmental disorders.
Serotonin’s especially rich innervation of limbic areas critical for emotional expression and
social behaviour and the extended ontogeny and apparent plasticity of the central serotonergic
system have provided additional support for its possible involvement.
As might be expected from its phylogenetically ancient role in neurodevelopment and
neural transmission, and its extensive CNS projections, 5-HT has been shown to play a
key role in a variety of behaviours and processes. Much of the early expression of 5-HT
appears related to its role as a growth factor and regulator of neuronal development. Thus,
in addition to functioning as a modulator of neural transmission, 5-HT appears to have
critical eﬀects on neurogenesis, morphogenesis, and synaptogenesis in the developing brain
[260].
In adult animals, 5-HT plays important roles mediating diverse autism-relevant behaviours,
including sleep, mood, arousal, aggression, impulsivity, and aﬃliation [151]. Reduced serotonergic
function has been associated with worsened sleep, depressed mood, altered arousal, increased
aggression, greater impulsivity, and reduced social behaviour. Genetic data have connected
5-HT-related genes to disorders deﬁned by symptoms in these areas of behaviour (e.g.
mood, social phobia, obsessive-compulsive, and anxiety disorders), and it is clear that the
serotonergic system is intimately interconnected with GABAergic and glutamatergic neurons
throughout the brain.
Empirical studies of 5-HT in autism include pharmacological treatment and challenge
studies, biochemical/neurochemical studies of 5-HT and related species, and genetic studies
of 5-HT-related genes. Drugs targeting the 5-HT transporter, including the 5-HT reuptake
inhibitors ﬂuoxetine, ﬂuvoxamine, and clomipramine, are now widely used in autism [183].
The reuptake inhibitors appear to aﬀect most aspects of autistic behaviour. Risperidone,
another frequently used medication, also acts predominantly through a serotonergic target,
the 5-HT2A receptor.
Platelet hyperserotonaemia has been especially well studied and is generally considered
the most robust and well-replicated biological ﬁnding in autism [7, 61, 6]. Most studies
have reported group mean elevations of 25-50% in platelet serotonin in persons with autism.
The mechanism of the alteration and its possible relationship to brain abnormalities remain
unknown. The platelet does not appear to be exposed to greater amounts of 5-HT; attention
has therefore focused on handling of 5-HT within the platelet. To date, no clear alteration
in the platelet has been identiﬁed although there is some suggestion that uptake may be
increased in some subjects with increased platelet levels.
Genes encoding a number of the components involved in 5-HT neural transmission
have been examined as possible contributors to the potentially relevant behaviours and
disorders mentioned. Research in autism has focused on the inﬂuence of 5-HT transporter
gene (SLC6A4) variants on risk to autism. Although taken together the studies do not
convincingly support a role for SLC6A4 variants in determining overall risk to autism,
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investigators are now examining allelic inﬂuences on the severity of speciﬁc aspects or
domains of autistic behaviour [230]. There have been several reports of variants in the
transporter promoter having modifying eﬀects in neuropsychiatry, and a recent report of
strong inﬂuence on vulnerability to stress [46]. Reports of eﬀects of 5-HT-related alleles
on therapeutic response to serotonergic antidepressants and atypical neuroleptics (in mood
disorders and psychosis, respectively) also tend to link 5-HT and autism [243].
At present, the areas of neuroimaging and postmortem brain research seem to oﬀer the
greatest potential for elucidating the role of serotonin in autism. The recent availability of
postmortem brain tissue has opened a wide window of opportunity. Reciprocal interchange
between imaging, neuropsychological, and postmortem research should be especially useful
and illuminating. Work on the mechanism of the platelet hyperserotonaemia may provide
critically important information regarding possible central 5-HT dysfunction; the advantages
of having identiﬁed a speciﬁc biochemical alteration in a delineated cell type might be best
exploited by applying gene array or expression technology to this question.
3.6 Lipids
Another genetic condition that shares autistic symptoms is Smith-Lemli-Opitz syndrome
(SLOS), an autosomal recessive, multiple malformation/mental retardation syndrome [213]
with an estimated incidence among individuals of European ancestry of one in 40,000 to
one in 60,000 births [150, 202, 39, 132], and a probable average carrier frequency of 1%
[132]. Principal abnormalities include a characteristic facial appearance, microcephaly,
hypotonia, postnatal growth retardation, 2-3 toe syndactyly, and hypogenitalism. In 1993,
SLOS was shown to be caused by a defect of cholesterol biosynthesis at the level of the 7-
dehydrocholesterol reductase [120, 226]. This defect impairs the conversion of 7-dehydrocholesterol
(7-DHC) to cholesterol, causing an increased level of 7-DHC in blood and tissues, and,
in most patients, decreased blood and tissue cholesterol levels. A major consequence of
these biochemical abnormalities is the alteration of normal embryonic and foetal somatic
development, causing postnatal abnormalities of growth, learning, language, and behaviour.
Cholesterol is necessary for the proper functioning of cells, and a defect in cholesterol
synthesis impairs multiple systems in the body. Decreased cellular cholesterol levels may
impair the development of cellular components and cellular function. Hedgehog proteins,
which are partially responsible for embryonic patterning, require cholesterol for proper
functioning. Individuals with SLOS have been found to have various CNS structural abnormalities
including holoprosencephaly. Studies in vitro have shown that the activity of receptors for
serotonin and other ligands is impaired in cholesterol-deﬁcient environments. Low cholesterol
levels impair the function of G-proteins, and thus the operation of metabotropic receptors.
Low cholesterol production in individuals with SLOS may thus illuminate the decreased
serotonergic functioning associated with autism.
Clinical data show that SLOS is associated with autism, and suggest that cholesterol
supplementation ameliorates autistic behavioural symptoms. Of 17 subjects with SLOS for
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whom the Autism Diagnostic Interview (ADI-R) [149] algorithm questions were administered,
9 (53%) met the ADI-R criteria for autism [225]. Of the 9 subjects who began cholesterol
supplementation before the age of 5.0 years, 2 (22%) met the ADI-R algorithm criteria for
autism at age 4.0 to 5.0 years. Of the remaining 8 subjects who began supplementation
after the age of 5.0 years or had not yet started supplementation, 7 (88%) met the ADI-R
algorithm criteria for autism.
Despite these behavioural similarities, the extent to which SLOS may share neurobiological
mechanisms with non-SLOS autism remains unclear. Individuals with SLOS manifest some
anatomical abnormalities [132] reminiscent of those often seen in autism: hypoplasia of
the corpus callosum, and of the cerebellum and particularly the vermis. However, the
developing macrocephaly in autism contrasts with a microcephaly in SLOS present from
birth and persisting into later life. The comparison between SLOS and autism at the level
of microanatomy remains an open question which could be usefully explored by quantitative
neuropathological studies. Even in the absence of proven shared mechanisms of neuropathology,
SLOS’s comorbidity with autism does suggest several lipid-associated pathways that may be
disrupted in non-SLOS autism and which may be examined for further clues. Abnormalities
of the lipid membrane may aﬀect membrane-associated proteins involved in neural or developmental
signalling [37]. Individuals may also have dysfunctions of sterol or steroid metabolism,
beginning in utero or later in life.
3.7 Immunological Signalling
In addition to genes related to speciﬁc neurotransmitter systems and to factors that directly
regulate gene expression, recent studies have suggested that genes within the major histocompatibility
complex (MHC, or HLA in humans), on chromosome 6p21.3, may encode predisposing factors
in autism [253, 78, 252] (but see [197]). Genes in this region encode products that are required
for self-nonself recognition by the adaptive immune system. In particular, an unusual number
of people with autism may share all or part of the extended MHC haplotype B44-SC30-DR4
[253, 78, 252, 232]. Evidence also exists for a link between autism and a null allele of the
C4B gene, in the class III MHC region, [254], and correspondingly low levels of C4b protein
[249] which is essential in activation of the classical complement pathway. The previously
mentioned possible involvement of the UBE3A gene also ties into MHC functioning, since the
peptide fragments presented by MHC molecules can be produced by the proteolytic activity
of ubiquitin ligase. Alterations in ubiquitin-related proteins or in other aspects of the peptide-
generating machinery can therefore be expected to have profound eﬀects on the intensity and
speciﬁcity of MHC-dependent immune signalling. These and other genetic correlates between
autism and immune-related genes could be causal, or alternatively may result from linkage
disequilibrium with nearby autism-associated genes that are as yet unknown.
In support of an immune signalling aetiology, there are many reports of elevated incidence
of immune disorders in the autistic population and in their ﬁrst-degreee relatives (reviewed
in [242, 138]). A subset of autism patients displays abnormal cell-mediated immunity and
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abnormal T cell populations and functions [217, 251, 255, 265, 83], reduced NK cell activity
[250], and lower Th1 and higher Th2-like cytokines [100]. In addition, autism patients often
exhibit abnormal humoural immune and autoantibody responses [259, 211, 210, 58]. Genetic
and symptomatic links between elevated serotonin levels and autism (see above) could also
contribute to immune dysfunction in autism; besides being a neurotransmitter, serotonin is
an immunomodulator [266]. Interestingly, immune dysfunction and strong genetic linkage
to the MHC are seen in dyslexia, another neurodevelopmental disorder that is similarly far
more prevalent in boys (e.g. [113, 40]). It appears that abnormal immune responses may be
predisposing but not suﬃcient to cause autism, since non-autistic ﬁrst-degree relatives often
share these abnormalities [57]. Rather, an environmental insult such as an infection may
interact with these genetically-based predisposing factors to cause autism.
The timing of any such environmental insult remains unclear, though the predictive
relationship between autistic symptoms later in development and increased brain volume
in the ﬁrst 2 to 12 months [65] seems to suggest a perinatal or prenatal time frame.
Some maternal viral infections are known to increase the risk for schizophrenia and autism
(reviewed in [52]), and in mice, experimental maternal inﬂuenza infection produces profound
anatomical, motor, and other behavioural defects reminiscent of autism spectrum disorders,
including hyperanxiety in novel situations and early postnatal macrocephaly [86, 208]. These
infectious links may be due to viral infection of the developing brain, or infection of the
pregnant mother. Infection in turn could lead to changes in expression of cytokines [168]
or neuronal class I MHC [116], or to production of autoantibodies [77]. While it is unknown if
autism is correlated with a change in neuronal MHC expression, maternal neuronal autoantibodies
have been associated with autism [77], and neuronal autoantibodies have also been detected
in autistic individuals themselves [210, 58].
Together, reports of genetic linkage to the MHC and immune comorbidity point to the
potential for an autoimmune aetiology for some cases of autism. It is worth noting that
viral or bacterial infections are suspected in the induction of many autoimmune diseases,
perhaps due to molecular mimicry or to sequelae of persistent subclinical infection [138].
Alternatively, it may be that the paired neurological and immunological symptoms of some
autism patients reﬂect the impact of abnormal neuronal function on the immune system,
with which it is known to have extensive crosstalk (reviewed in [1]). A third possibility
is that immune and neurological symptoms are parallel manifestations of a single form of
genetic or metabolic disorder.
This last possibility is interesting in light of the recent discovery that class I MHC,
in addition to its well-characterised role in immune function, is expressed in neurons and is
critical for normal brain development and function [62, 116]. This novel ﬁnding suggests that
defects in MHC function could give rise, in parallel, to both immunological and neurodevelopmental
dysfunctions (reviewed in [34]). Although originally not thought to be expressed by normal,
uninjured neurons, class I MHC was identiﬁed in an unbiased screen for genes involved in
activity-dependent reﬁnement of developing visual projections [62]. Here, as in many other
regions of the developing brain, initial projections are large and imprecise, and patterned
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neuronal activity arising in the periphery is necessary for the removal of inappropriate
connections and stabilisation of appropriate ones. This process is critical to achieving
mature patterns of connectivity, and in mammals occurs in early postnatal life. Strikingly,
class I MHC mRNA is regulated by the spontaneous activity that drives reﬁnement of the
developing visual system [62], and is expressed by neurons precisely at the times and places of
widespread activity-dependent structural and functional plasticity, both during development
and in the adult [62, 116]. This positive association between MHC signalling and synaptic
development is reinforced by the negative eﬀects of MHC knockouts. Mice deﬁcient for class
I MHC signalling retain the immature pattern of visual connections, presumably due to a
failure of activity-dependent reﬁnement [116]. In addition, hippocampal synapses in these
mice are not weakened in response to patterned activity, and instead are inappropriately
strengthened. Both of these defects are also found in mice lacking CD3ζ, a component
of many known receptors for class I MHC [116]. These changes in plasticity are not a
nonspeciﬁc eﬀect of immune compromise, since neural plasticity is normal in even more
severely immunocompromised (RAG1−/−) mutant mice [116]. Thus class I MHC is required,
either developmentally or acutely, for activity-dependent synaptic weakening and removal
of inappropriate connections, changes that are crucial for normal brain maturation and
function [116, 34]. The idea that shared molecular mechanisms may underlie both neuronal
plasticity and cellular immunity is further supported by the fact that much of the MHC
signal transduction machinery found in the immune system is also expressed in neurons
(reviewed in [34]).
In the context of the hypothesis of abnormal connectivity in autistic brain development,
the implications of such a failure of synaptic weakening and synaptic speciﬁcity are straightforward.
The combination of early brain overgrowth, immunological abnormalities, and genetic linkage
to the MHC is consistent with the possibility that a defect in MHC signalling is causal
for a subset of people with autism. Defects in MHC signalling lead to abnormal activity-
dependent reﬁnement and plasticity in the developing visual system, the adult hippocampus,
and perhaps elsewhere in the brain. Abnormal information processing later in life could
stem from the excessive connectivity laid down during development as well as persistent
abnormal potentiation of synaptic strength. The patterns of expression of various MHC
genes are diverse, varying with neuron type, brain region, and age [116]. This chemical
diversity provides a route whereby a general abnormality in MHC signalling may interact
with normal development to produce speciﬁc patterns of abnormality.
To date, the connections between autism and immune genes and dysfunction have been
interpreted as support for an autoimmune or infectious aetiology. It may be that class I
MHC expression by populations of neurons at a given time in development confers selective
vulnerability to autoimmune attack, particularly if T cells are entering the brain in large
numbers, as they do during some infections. It would therefore be of interest to determine if
neurons aﬀected early in autism, such as cerebellar Purkinje cells and granule cells, express
high levels of MHC around the time of onset. In addition, it would be of great value to know
if MHC is expressed in abnormal patterns or levels in the developing autistic brain, although
such experiments await the further reﬁnement and validation of animal models of autism.
20
The studies linking immune genes and immunological functions to autism are fragmentary
and a topic of heated debate. Methodological diﬀerences, small sample sizes, and a lack of
appropriate control groups, as well as likely heterogeneity in aetiology and pathology, all
hamper interpretation of conﬂicting studies. Causal heterogeneity in particular will likely
frustrate attempts to determine genetic, functional, and anatomical correlates until other,
perhaps biochemical, diagnostic criteria are developed to classify causal subtypes of autism.
To that end, the hypothesis that MHC signalling is involved in the aetiology of a subset of
cases of autism suggests candidate markers and neural substrates that may identify one such
population. The current data appear to link altered immune function to abnormal neuron
development through shared molecular mechanisms, and oﬀer testable hypotheses regarding
the possible relationship to autism. Understanding the role of immune molecules in brain
maturation and function may ultimately lead to unexpected new strategies for the screening,
treatment, and prevention of autism and other neurodevelopmental disorders.
4 Animal Models
Although several primate models of autism have been developed [106, 152], research on
neurodevelopmental abnormalities and treatments for autism has had to cope with a dearth of
non-primate animal models [63, 193]. Targeting relatively simple behaviours in rodent models
has proven useful in the development of pharmacological targets in other neuropsychiatric
diseases such as schizophrenia and aﬀective disorders [97, 147]. Establishing the face,
predictive, and construct validity of an animal model of autism may prove extremely useful
in advancing understanding of autism’s neuropathology and in screening potential therapies.
Approaches to animal models of neuropsychiatric disease involve modelling the aetiology or
pathophysiology of the disease (e.g. producing mice with cerebellar pathology) or modelling
particular behavioural attributes (e.g. studying animals with abnormal social interactions
or deﬁcient sensorimotor gating).
If people with autism are hyper-responsive to sensory stimuli, then existing methods of
examining sensory responsiveness may be useful in deﬁning endophenotypes and developing
animal models of autism. One approach to measuring sensory processing arises in the context
of sensorimotor gating. Prepulse inhibition (PPI) of the startle response is a cross-species
measure of the normal decrement in startle when a barely detectable prestimulus immediately
precedes (30-500ms) a startling stimulus [123, 98, 79]. PPI appears to reﬂect the activation
of a ubiquitous centrally mediated behavioural ‘gating’ process, and has been widely applied
in studies of information processing and cognition in animals and humans. In particular, the
inhibitory processes activated by the weak ‘prepulse’ and the resulting decrement in startle
amplitude have been used as an operational measure of sensorimotor gating. Studying PPI
has enabled a focus on well-deﬁned measures of information processing having substantial
homology among diﬀerent species and, in the case of schizophrenia, signiﬁcant predictive
validity for treatments [221]. As reviewed elsewhere, schizophrenia-like deﬁcits in PPI have
been mimicked in animals using both pharmacological [96] and anatomical manipulations
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[222].
Deﬁcits in PPI have been observed in schizophrenia [35], obsessive-compulsive disorder
[220], Huntington’s disease [223], nocturnal enuresis and Attention Deﬁcit Disorder [164],
and Tourette syndrome [47]. Although an earlier study of autism showed no abnormality
in PPI [165], a more recent examination, parametrised in terms of prestimulus amplitude
and prestimulus-to-stimulus interval, revealed a selective impairment in the inhibition of
startle response at high prestimulus amplitude and longer interstimulus intervals [155].
While normal subjects showed the typical pattern of increased prepulse inhibition at higher
prestimulus intensities (12 dB versus 4 dB) and longer interstimulus intervals (120ms versus
30ms), people with Asperger syndrome did not. This failure to make use of extra processing
time to rapidly modify response bias is reminiscent of results on slowed shifting of attention
in autism (e.g. [236]), and the absence of an eﬀect of prepulse amplitude suggests abnormal
sensory responsiveness – a possibility supported by skin conductance ﬁndings of abnormally
high tonic arousal [216] and abnormally high phasic response to stimuli [241] in autism.
Similar ﬁndings of high arousal [30] and high responsiveness [156] in FXS support the idea
that these abnormal sensory phenomena may be markers of abnormal neural development.
More comprehensive studies assessing startle plasticity in adults and children with autism
are warranted, and are currently underway (William Perry, personal communication).
Sensorimotor gating abnormalities similar to those in human neuropsychiatric conditions
have been produced in rats by a variety of neurodevelopmental manipulations. Models
include alterations of the intrauterine environment (e.g. viral insult, neurotoxin exposure,
prenatal maternal stress), birth complications [240], postnatal maternal and/or social deprivation
[85, 258], and neonatal ventral hippocampal lesions [146]. The developmental model most
extensively studied for its eﬀects on PPI has been post-weaning social isolation, a manipulation
that induces profound abnormalities in behaviour, drug responses, and neurochemistry [185].
Neurodevelopmental animal models like those developed for schizophrenia are now being
brought to bear on autism. Some of these autism models are based on prenatal exposure
to teratogens such as Borna disease virus [182] or valproic acid [119]. Others derive from
ﬁndings of abnormal cerebellar anatomy in people with autism, and include both mutant
animals with speciﬁc cerebellar malformations [49, 139] and animals with surgical lesions of
the midline cerebellum [32]. Several such cerebellar models have begun to ﬁnd application
in the study of sensorimotor gating and other behaviours relevant to autism: deﬁcits in
PPI have been observed in heterozygous reeler mice [238] and in mice homozygous for the
cerebellar deﬁcient folia (cdf) mutation [167].
A further model is based on the hypothesis of low signal-to-noise as a basis of autistic
brain development: if this is the case, developmental errors similar to those in autism
ought to be able to be induced by manipulating signal-to-noise directly, independently
of any neurochemical antecedents. A straightforward way of implementing such a direct
manipulation is to supply the developing brain with consistently noisy sensory inputs. In
rats reared in continuous 70dB acoustic noise, neurons in primary auditory cortex retain
into adulthood the immature pattern of broad, high-frequency tuning curves and imprecise
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tonotopy typical of the earliest stage of auditory development [51]. This physiological ﬁnding
of broad tuning in the auditory system seems very much akin to the psychophysical ﬁnding
of abnormal bandwidth of auditory ﬁlters in people with high-functioning autism [180].
In addition to retarding the emergence of normal activity-dependent patterns of neural
tuning, developmental exposure to noise prolongs the critical period during which any input,
regardless of behavioural context, is signiﬁcant for activity-dependent plasticity [51]. A delay
of this transition from unconditional plasticity to context-dependent plasticity may underlie
the ease with which people with autism learn arbitrary associations, and the diﬃculty with
which they incorporate behavioural context into such learning. Furthermore, a delayed and
abnormal closing of this critical period may be the trigger for the onset of autistic regression
during the second or third year of life.
Inevitably animal models will play an important role in future research on the causes and
cures for autism. Creative translational brain-behaviour designs will be needed, wherein tests
demonstrating speciﬁc brain-behaviour relationships in children with autism are formatted
for animal model studies. For instance, a recent human study showed that when allowed
to explore freely an open area containing novel objects, children with autism spent less
time exploring the novel information than normal children, and that the more abnormal
the exploration behaviour, the smaller the cerebellar vermis [173]. Such a study design can
be easily formatted for testing animal models of candidate genetic or non-genetic causes of
autism, and in fact several candidate models already exist. The GS guinea pig, a mutant with
malformation of cerebellar vermal lobules VI and VII, shows decreased exploratory behaviour
[49], as do Purkinje cell degeneration mutant mice [140]. Speciﬁc loss of Purkinje cells in
cerebellar vermal lobules VI and VII in L1CAM knockout mice is associated with decreased
exploration and stereotyped circling in a novel environment [131, 90]. Rats with cerebellar
lesions show deﬁcits in long-term habituation of the acoustic startle response [144] and
increased spontaneous motor activity and perseverative behaviour [32]. As the deﬁnition of
human behavioural endophenotypes in autism proceeds, measurable, homologous behaviours
can be quantiﬁed in animal models. Prepulse inhibition and other forms of startle modulation
(e.g. fear potentiated startle) may be useful in constructing such animal behavioural homologues.
5 Research Imperatives
5.1 Phenotypes within and beyond the Diagnosis
To those who treat patients with autism spectrum disorders, or who work with them as
researchers or caregivers, it can often seem as if there are as many kinds of autism as
there are people with autism. Since the diagnosis of autism rests on broad and entirely
behavioural criteria, studies whose inclusion criteria follow the diagnostic criteria are liable
to recruit subject groups that are heterogeneous in terms of ultimate causes. Reducing this
heterogeneity demands a more detailed taxonomy, extending not only within the diagnosis
but also outside it. The accepted wisdom has been to restrict studies to only the most
23
severe cases – for example those patients who satisfy both ADI-R and ADOS criteria
and whose clinical diagnoses exclude Asperger syndrome and PDD-NOS. Although this
strategy certainly reduces heterogeneity, it puts blinders on eﬀorts to identify behavioural
endophenotypes. In contrast, broadening studies beyond the strict diagnosis of autism
holds a great deal of promise for identifying which components of the autistic syndrome
are genetically transmitted, and how these components interact. The early results of such
work reveal familial patterns of repetitive behaviours, impaired nonverbal communication,
and impaired or delayed development of phrase speech, but not social interaction or verbal
communication [209].
Autism may well occur when several root factors combine to produce a core dysfunction –
a dysfunction which we have suggested may involve neural signal-to-noise – to a degree that
brings on a grand change in developmental course and produces autism’s many symptoms.
Information on the abnormal events surrounding this critical developmental event becomes
much more valuable when it can be contrasted with information on what happens when
the event is avoided. Such a contrast can be obtained by studying siblings and other
family members of patients with autism, people who presumably share some of the genetic
susceptibility factors but in whom those factors have not become magniﬁed into the full
syndrome of autism. A wealth of behavioural data suggests that such factors are operative
in ﬁrst-degree relatives and do produce subclinical abnormalities. Siblings of autistic children
show a cognitive proﬁle reminiscent of that of autism itself, with superior spatial and
verbal span, poor set-shifting, poor planning, and poor verbal ﬂuency [115]. Parents of
autistic children perform in the superior range on the Embedded Figures Test [20], visual
search tasks [163], and other tasks that require processing of parts and details [102], but
are below normal performance at inferring mental state from facial expression [20], a task
that demands conﬁgural and integrative processing. In addition, parents share diﬃculties
in pragmatic language tasks [87], impairments in some tasks that tap executive function
[114], and autistic personality characteristics such as rigidity, aloofness, and anxiety [179,
178]. Many ﬁrst-degree relatives show a disparity between performance IQ and verbal
IQ, with the performance score being lower [89, 177, 87] due to impairment on Picture
Arrangement and Picture Completion, both of which demand attention to global, contextual
information. These subtle characteristics of the broader autism phenotype are visible in the
cognitive skills that relatives tend to develop: occupations in engineering, which demands
meticulous attention to detail, are over-represented in the fathers and grandfathers of people
with autism [23] and, conversely, the incidence of autism is increased in the families of
engineers, mathematicians, and physicists [19]. Siblings are at greater risk than the general
population for a wide array of cognitive and aﬀective disorders [176, 10], and there is some
epidaemiological evidence relating autism to familial history of aﬀective disorder [81].
If the cognitive proﬁle in siblings is, as it seems, reﬂective of that in autism, then the same
may be true at the levels of neuroanatomy, neurophysiology, and neurochemistry. Studies
of ﬁrst-degree relatives at these levels of analysis can expose primary factors closer to the
roots of autistic brain development, unobscured by so many of the secondary developmental
sequelae that may overshadow or mask such factors in autism probands. In particular, there
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is a wealth of electrophysiological and morphometric ﬁndings in autism whose value would
be greatly augmented if the same experiments and measures were applied in autism relatives,
and the results compared. Do relatives manifest to any degree the anatomically over-
generalised activation found in autism probands during attentional tasks? Is focused spatial
attention associated with abnormally modulated mid-latency visual evoked potentials as it is
in autism probands? Are there any changes in the amplitude or latency of frontal negativities,
or in the late positive component? Do relatives show any abnormality in cerebellar volume,
or in cross-sectional area of the corpus callosum? What about head circumference and early
overgrowth of the frontal lobes? Many of these comparative questions can be answered
quite easily, and should be addressed. Where diﬀerences exist, they may be subtle, and
large groups of subjects may be required in order to achieve suﬃcient statistical power. As
autism susceptibility genes begin to be identiﬁed, these non-autistic relatives will be of the
utmost value in deﬁning the behavioural and physiological phenotypes with which single
susceptibility factors are associated.
The potential for large-scale secondary dysfunctions to mask more primary abnormalities
has implications for studies within autism probands, too. A great deal of research attention
has been devoted to autism’s most apparent and most debilitating symptoms, those that
make up the diagnostic triad of impaired social interaction, impaired communication, and
restricted and repetitive interests and behaviours. Even physiological studies have addressed
complex social capacities such as theory-of-mind [22] and emotion perception [76]. Observations
at all levels of behavioural and physiological complexity are useful in reverse-engineering
autistic development. However, in concentrating exclusively on the most diagnostic features
of autism, such work may be overlooking cognitive and perceptual features at low levels of
processing that are closer to autism’s core dysfunction. There is a great need for further
exploration of the neurophysiology associated with low-level perceptual abnormalities. It is
quite remarkable and diﬃcult to fathom that we currently have more functional imaging data
about how the autistic brain processes a face or a theory of mind than we do about the way it
processes, say, location, colour, orientation, or spatial frequency; at what level of processing
do the perceptual and cognitive abnormalities begin? It is also important to recognise
that absence of behavioural performance or functional activation does not necessarily imply
incapacity of the corresponding brain subsystems. Rather, an apparent lack may be due to
failure to engage an intact capacity. The proper stimuli or experimental paradigm can bring
out such hidden abilities.
The ﬁnding of early brain overgrowth illustrates the importance of looking for primary
abnormalities at the youngest possible ages, before all of the secondary changes have occurred.
Although autism currently cannot be decisively diagnosed until the age of 5 years, its sibling
recurrence risk of 4.5% opens the possibility of conducting the study in advance of the
diagnosis. After the collection of data from all at-risk siblings, observations of siblings who
do not meet full criteria at age 5 can be excluded from the autism sample. These observations
of siblings who turn out not to have autism are not wasted, since, as noted previously, the
sibling group is an informative contrast both to the autism group and to unrelated control
subjects.
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In addition to these more traditional, cognitively based elements of behaviour, attention
must be paid to even lower-level aspects of the phenotype. Parent reports are rife with
anecdotal observations of low-level dysfunctions. Motor abnormalities, in particular, may be
one of autism’s earliest signs, appearing within the ﬁrst year of life [17]. Abnormal gait is
common in autism [245, 101], and motor clumsiness seems particularly prominent in Asperger
syndrome [214]. Other oft-reported abnormalities (e.g. gastrointestinal problems, blink rate,
pupillary dilation), and the unproven interventions that have been designed around some of
them, may yet contain a kernel of truth and should be subjected to controlled study.
5.2 A Synthetic Approach
Most experimental observations of autism yield correlations rather than deﬁnite causal
relationships, and these correlations often exist in a vacuum: it is possible to implicate
a chromosomal locus without knowing what genes it contains, a gene without knowing the
function of its protein product, a protein without knowing its physiologic eﬀect, and so forth.
Connecting the many stages from genetics and biochemistry to brain structure and function
and behaviour demands studies that bridge these levels of analysis.
Postmortem studies and in vivo MRS studies aimed at elucidating the neuronal and
molecular bases of early brain growth abnormalities in cerebellar and cerebral white matter
and cerebral grey matter are needed. Studies can and should be designed to demonstrate
explicitly relationships between such postmortem microscopic ﬁndings and in vivo MRI-
based macroscopic eﬀects. Also, detailed knowledge of brain growth defects may help guide
the eﬀort to create more developmentally realistic animal models of the disorder. Techniques
such as MRI morphometry and event-related potentials make it possible to associate speciﬁc
sites of brain abnormality with speciﬁc types of neurobehavioural deﬁcits. Event-related
potentials and other brain-behaviour correlation studies have elucidated relationships between
anatomical sites of abnormality and deﬁcits in visual selective attention, shifting attention,
motor activation, motor learning, visuospatial exploration, and orienting attention. An
important hypothesis for future research is that the age of onset, rate, and duration of
aberrant brain growth are related to the severity and age of onset of autistic behaviours.
Like the individuals whom it seeks to understand, the ﬁeld of autism research often falls
victim to a sort of weak central coherence. Its challenge is to unify a complex set of local
observations and details into coherent explanations of the autistic syndrome. Isolation of
speciﬁc endophenotypes and examination of contributing genes will aid in uncovering the
neurobiological roots of autism’s core dysfunctions, while targeting low-level processes and
examining early stages of development will highlight the steps through which those core
dysfunctions unfold into autism’s complex behavioural syndrome.
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